BioMarin Pharmaceutical Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 58.51 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.33B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Details
| Name | BioMarin Pharmaceutical Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 3221 |
| Founded | 1996 |
| Ipo Date | 1999-07-23 |
| Ceo | Alexander Hardy |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US09061G1013 |
| Cusip | 09061G101 |
| Cik | 0001048477 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Alexander Hardy | President, Chief Executive Officer and Director |
| Brian R. Mueller CPA | Chief Financial Officer and Executive Vice President of Finance |
| Dr. C. Greg Guyer Ph.D. | Executive Vice President and Chief Technology Officer |
| Cristin Hubbard | Executive Vice President and Chief Commercial Officer |
| Dr. Gregory Friberg M.D. | Executive Vice President and Chief Research and Development Officer |
| Rashmi Eshwar Ramchandani | Vice President, Chief Accounting Officer and Principal Accounting Officer |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer and Senior Vice President of Research and Early Development |
| Arpit Dave | Executive Vice President, Chief Digital and Information Officer |
| George Eric Davis J.D. | Executive Vice President, Chief Legal Officer and Secretary |
| Cara Bauer Ph.D. | Executive Vice President and Chief People Officer |
Contact
| Address | 770 Lindaro Street, San Rafael, California 94901, United States |
| Phone | 415 506 6700 |
| Website | https://www.biomarin.com |